The US Patent Office issues new patents every Tuesday. New Zealand assignees generally get one or two healthcare and biotech-related patents a month. Here are the 12 US patents relevant to New Zealand's Life Sciences sector that issued between 6 January 2015 and 29 December 2015. For patents issued in the last twelve months click here.
|
US Patent 9,212,204
|
Title: Treatment of Rett Syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Issued: 15 December 2015 Assignee: Neuren Pharmaceuticals (ASX: NEU) |
Description: This patent covers Neuren's lead NNZ-2566 molecule for the treatment of the autism spectrum disorder Rett Syndrome.
|
|
US Patent 9,198,430
|
Title: Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
Issued: 1 December 2015 Assignee: Bayer New Zealand |
Description: This patent covers the combination of a macrocyclic lactone such as Doramectin, plus levamisole, for the treatment of parasitic infestations.
|
|
US Patent 9,119,851
|
Title: Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
Issued: 1 September 2015 Assignee: Neuren Pharmaceuticals (ASX: NEU) |
Description: This patent covers Neuren's NNZ-2591 product for the treatment of cognitive impairment.
|
|
US Patent 9,102,743
|
Title: Immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and uses thereof
Issued: 11 August 2015 Assignee: Massey University (50%), Institut Pasteur (France, 50%) |
Description: This patent covers a vaccine for Johne's disease.
|
|
US Patent 9,101,632
|
Title: Kinase inhibitors, prodrug forms thereof and their use in therapy
Issued: 11 August 2015 Assignee: Auckland UniServices (University of Auckland) |
Description: This patent covers hypoxia-activated prodrugs that give increased tumour-selectivity to novel kinase inhibitors.
|
|
US Patent 9,095,430
|
Title: Biomaterials with enhanced properties and devices made therefrom
Issued: 4 August 2015 Assignee: Southern Lights Ventures |
Description: This patent covers glutaraldehyde-fixed neonatal pericardial tissue used to percutaneous heart valve leaflets.
|
|
US Patent 9,079,859
|
Title: Synthetic lethal targeting of glucose transport
Issued: 14 July 2015 Assignee: Auckland UniServices (University of Auckland) (33%), Stanford University (US, 33%), Ruga Corp (US, 33%) |
Description: This patent covers GLUT1 inhibitors to treat cancer via the HIF pathway.
|
|
US Patent 9,073,916
|
Title: Prodrug forms of kinase inhibitors and their use in therapy
Issued: 7 July 2015 Assignee: Auckland UniServices (University of Auckland) |
Description: This patent covers hypoxia-activated prodrugs that give increased tumour-selectivity to novel kinase inhibitors.
|
|
US Patent 9,045,505
|
Title: Nitric oxide donors
Issued: 2 June 2015 Assignee: University of Otago (50%), Medical Research Council (UK, 50%) |
Description: This patent covers nitrix oxide donors targeted to the mitochondria.
|
|
US Patent 9,040,485
|
Description: This patent covers part of CuroNZ's library of neural regeneration peptides.
|
|
US Patent 8,987,244
|
Title: Preventing and/or treating cardiovascular disease and/or associated heart failure
Issued: 24 March 2015 Assignee: PhilERA (Professor Garth Cooper) |
Description: This patent covers the use of new formulations of copper chelation drugs to treat various chronic diseases.
|
Copyright © 2016 NDF Research